45
Views
6
CrossRef citations to date
0
Altmetric
Original

Comparison of Conventional Dose and Double Dose Carboplatin in Patients Receiving Cyclophosphamide Plus Carboplatin for Advanced Ovarian Carcinoma: A North Central Cancer Treatment Group Study

, M.D., , Ph.D., , M.D., , M.D., , M.D., , M.D., , M.D., , M.D., , M.D., , M.D. & , M.D. show all
Pages 597-602 | Published online: 31 Jul 2001

REFERENCES

  • Levin L., Hryniuk W. M. Dose Intensity Analysis of Chemotherapy Regimens in Ovarian Carcinoma. J. Clin. Oncol. 1987; 5: 756–767
  • Edmonson J. H., Hartmann L. C., Long H. J., Colon-Otero G., Fitch T. R., Jefferies J. A., Braich T. A., Maples W. J. Granulocyte-Macrophage Colony-Stimulating Factor: Preliminary Observations on the Influences of Dose, Schedule, and Route of Administration in Patients Receiving Cyclophosphamide and Carboplatin. Cancer 1992; 70: 2529–2539
  • Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function. J. Clin. Oncol. 1989; 7: 1748–1756
  • McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Look K. Y., Partridge E. E., Davidson M. A Phase III Trial Comparing Cisplatin/Cytotoxan (PC) and Cisplatin/ Taxol (PT) in Advanced Ovarian Cancer. Proc. Am. Soc. Clin. Oncol. 1993; 12: 255
  • Thigpen J. T. Dose Intensity in Ovarian Carcinoma: Hold, Enough?. J Clin. Oncol. 1997; 15: 1291–1293
  • Legros M., Dauplat J., Fleury J., Cure H., Suzanne F., Chassagne J., Bay J. O., Sol C., Canis M., Condat P., Choufi B., Tavernier F., Glenat C., Chollet P., Plagne R. High-Dose Chemotherapy with Hematopoietic Rescue in Patients with Stage III to IV Ovarian Cancer: Long-Term Results. J. Clin. Oncol. 1997; 15: 1302–1308
  • Stiff P. J., Bayer R., Kerger C., Potkul R. K., Malhotra D., Peace D. J., Smith D., Fisher S. G. High-Dose Chemotherapy with Autologous Transplantation for Persistent/ Relapsed Ovarian Cancer: A Multivariate Analysis of Survival for 100 Consecutively Treated Patients. J. Clin. Oncol. 1997; 15: 1309–1317

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.